SG Americas Securities LLC Buys 323,747 Shares of Day One Biopharmaceuticals, Inc. $DAWN

SG Americas Securities LLC raised its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 1,228.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 350,092 shares of the company’s stock after purchasing an additional 323,747 shares during the quarter. SG Americas Securities LLC owned 0.34% of Day One Biopharmaceuticals worth $3,263,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in DAWN. AIGH Capital Management LLC purchased a new position in shares of Day One Biopharmaceuticals in the third quarter worth $10,719,000. AlphaQuest LLC raised its holdings in Day One Biopharmaceuticals by 1,065.6% during the 3rd quarter. AlphaQuest LLC now owns 185,006 shares of the company’s stock valued at $1,304,000 after buying an additional 169,134 shares during the last quarter. Schroder Investment Management Group purchased a new stake in Day One Biopharmaceuticals during the 2nd quarter valued at $1,171,000. Mak Capital One LLC purchased a new stake in Day One Biopharmaceuticals during the 3rd quarter valued at $10,212,000. Finally, Geode Capital Management LLC grew its holdings in Day One Biopharmaceuticals by 11.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company’s stock worth $11,132,000 after acquiring an additional 171,964 shares during the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Trading Up 0.1%

Shares of NASDAQ DAWN opened at $21.45 on Friday. Day One Biopharmaceuticals, Inc. has a 12 month low of $5.64 and a 12 month high of $21.47. The firm has a market capitalization of $2.22 billion, a PE ratio of -20.83 and a beta of -1.74. The firm has a fifty day simple moving average of $15.40 and a two-hundred day simple moving average of $10.90.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. The company had revenue of $53.72 million for the quarter, compared to the consensus estimate of $49.81 million. On average, sell-side analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on DAWN. Wedbush reaffirmed a “neutral” rating and set a $21.50 price objective (down from $30.00) on shares of Day One Biopharmaceuticals in a research note on Monday, March 9th. Needham & Company LLC cut Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 6th. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Friday, March 6th. HC Wainwright reaffirmed a “neutral” rating and set a $21.50 price target (down from $22.00) on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 10th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $21.50 price objective (down from $27.00) on shares of Day One Biopharmaceuticals in a report on Wednesday, March 11th. One analyst has rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of “Hold” and a consensus price target of $23.29.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Lauren Merendino sold 5,814 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $67,442.40. Following the sale, the insider directly owned 60,157 shares of the company’s stock, valued at approximately $697,821.20. The trade was a 8.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Adam Dubow sold 6,395 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $74,182.00. Following the transaction, the insider owned 72,694 shares in the company, valued at $843,250.40. This trade represents a 8.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 36,461 shares of company stock valued at $422,948 over the last ninety days. 6.20% of the stock is owned by corporate insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.